The phosphoinositide-3 kinase-AKT-mammalian target of rapamycin (mTOR) pathway has been identified as a candidate pathway in bladder cancer progression in several recent clinicopathological studies [8,9]. The gene discussed is MTOR; the disease is urinary bladder cancer.